Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Fuji
Deloitte
AstraZeneca
QuintilesIMS
Dow
Covington
Express Scripts
Accenture
McKinsey

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,916,595

« Back to Dashboard

Which drugs does patent 5,916,595 protect, and when does it expire?


Patent 5,916,595 protects ALTOPREV and is included in one NDA.

This patent has twenty-six patent family members in twelve countries.

Summary for Patent: 5,916,595

Title: HMG co-reductase inhibitor
Abstract:A controlled release dosage formulation is described which is based on a combination of: (a) a compressed tablet core which contains an alkyl ester of a hydroxy substituted naphthalene derivative a pharmaceutically acceptable, water swellable polymer and an osmotic agent; and (b) an outer coating layer which completely covers the osmotic core and comprises a pH sensitive coating agent and a water insoluble polymer.
Inventor(s): Chen; Chih-Ming (Davie, FL), Chou; Joseph (Coral Springs, FL), Wong; David (Hollywood, FL)
Assignee: Andrx Pharmaceutials, Inc. (Fort Lauderdale, FL)
Application Number:08/989,253
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Covis Pharma Bv
ALTOPREV
lovastatin
TABLET, EXTENDED RELEASE;ORAL021316-001Jun 26, 2002DISCNNoNo► Subscribe► Subscribe
Covis Pharma Bv
ALTOPREV
lovastatin
TABLET, EXTENDED RELEASE;ORAL021316-002Jun 26, 2002RXYesNo► Subscribe► Subscribe
Covis Pharma Bv
ALTOPREV
lovastatin
TABLET, EXTENDED RELEASE;ORAL021316-003Jun 26, 2002RXYesNo► Subscribe► Subscribe
Covis Pharma Bv
ALTOPREV
lovastatin
TABLET, EXTENDED RELEASE;ORAL021316-004Jun 26, 2002RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,916,595

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,679,534HMG-CoA reductase inhibitor extended release formulation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,916,595

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office1035842► Subscribe
Germany69832092► Subscribe
Germany20023538► Subscribe
Canada2315329► Subscribe
Spain2252872► Subscribe
United Kingdom0210619► Subscribe
United Kingdom2371748► Subscribe
Israel149524► Subscribe
Japan2002508311► Subscribe
Hong Kong1050134► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Baxter
McKesson
Medtronic
Colorcon
Argus Health
Mallinckrodt
Boehringer Ingelheim
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot